

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.9	88.3	(35.4-181.9)	Male	5	5.7	87.8	(28.3-204.8)
Female	2	2.6	nc	(nc-nc)	Female	7	4.6	152.7	(61.2-314.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.8	125.6	(45.9-273.5)
Female	25	32.1	77.8	(50.4-114.9)	Female	0	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	11.9	134.2	(76.7-218.0)	Female	4	3.2	nc	(nc-nc)
Female	9	9.6	94.2	(43.0-178.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.5	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	33.5	89.5	(60.4-127.8)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	8	4.3	184.4	(79.4-363.3)	<u>Testis</u>				
Female	3	2.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	7	5.0	140.2	(56.2-288.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.8	nc	(nc-nc)	Female	6	7.1	84.0	(30.7-182.9)
Female	3	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	114	116.0	98.3	(81.1-118.1)
Male	2	2.2	nc	(nc-nc)	Female	95	103.5	91.8	(74.3-112.2)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	15.2	124.8	(75.1-194.8)					
Female	12	13.3	90.4	(46.7-158.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	24.9	104.4	(68.2-153.0)	Male	15	15.3	98.0	(54.8-161.6)
Female	8	9.1	87.4	(37.7-172.3)	Female	4	11.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	4.6	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	Female	7	2.9	243.0	(97.3-500.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	0.8	nc	(nc-nc)	Male	16	13.2	121.6	(69.5-197.6)
Female	76	80.8	94.0	(74.1-117.7)	Female	9	11.5	77.9	(35.6-148.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	6	9.1	66.3	(24.2-144.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	34.6	60.7	(37.6-92.8)	Female	5	8.6	57.9	(18.7-135.1)
Female	22	33.7	65.3	(40.9-98.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	7.4	148.2	(73.9-265.2)
Male	3	6.3	nc	(nc-nc)	Female	5	8.0	62.7	(20.2-146.3)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	72	88.9	81.0	(63.4-102.0)
Male	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	3.8	nc	(nc-nc)
Male	11	11.4	96.5	(48.1-172.6)	<u>Testis</u>				
Female	3	6.8	nc	(nc-nc)	Male	5	3.7	135.8	(43.8-316.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	3.9	155.4	(56.8-338.4)	Male	5	3.9	129.0	(41.6-300.9)
Female	1	1.0	nc	(nc-nc)	Female	7	10.5	66.8	(26.8-137.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	8.2	nc	(nc-nc)	Female	21	17.8	118.2	(73.2-180.7)
Female	7	6.3	110.3	(44.2-227.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	296	323.3	91.5	(81.4-102.6)
Male	4	5.5	nc	(nc-nc)	Female	254	296.1	85.8	(75.6-97.0)
Female	1	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	51	45.3	112.5	(83.7-147.9)					
Female	42	42.6	98.6	(71.0-133.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.9	101.8	(40.8-209.8)	Male	4	4.9	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.1	121.8	(39.3-284.3)
Female	19	28.1	67.6	(40.7-105.6)	Female	7	3.3	209.8	(84.1-432.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	6	3.2	187.6	(68.5-408.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	10.3	87.6	(40.0-166.3)	Female	3	2.8	nc	(nc-nc)
Female	7	8.8	79.5	(31.9-163.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.2	nc	(nc-nc)
Male	5	2.0	253.7	(81.7-591.9)	Female	0	2.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	36	28.4	126.9	(88.8-175.7)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.1	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	8	4.3	185.0	(79.7-364.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.5	nc	(nc-nc)	Female	6	6.1	97.8	(35.7-212.8)
Female	2	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	115	99.4	115.7	(95.5-138.9)
Male	2	1.9	nc	(nc-nc)	Female	84	92.2	91.1	(72.7-112.8)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	13.2	113.9	(63.7-187.9)					
Female	13	12.0	108.7	(57.8-186.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	8	5.8	137.4	(59.2-270.7)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	5	6.0	83.5	(26.9-194.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.4	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	2.9	nc	(nc-nc)	Female	17	21.7	78.4	(45.6-125.5)
Female	3	2.6	nc	(nc-nc)	Female	18	19.5	92.5	(54.8-146.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	37.1	94.4	(65.7-131.2)	Male	24	23.0	104.4	(66.9-155.3)
Female	16	14.2	112.3	(64.2-182.4)	Female	21	18.8	111.5	(69.0-170.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.8	147.2	(70.5-270.8)	Male	7	5.8	119.8	(48.0-246.8)
Female	6	5.8	103.3	(37.7-224.9)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	15	19.6	76.6	(42.8-126.3)
Female	136	136.4	99.7	(83.6-117.9)	Female	23	18.2	126.1	(79.9-189.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.7	106.1	(38.8-231.0)	Male	16	14.4	111.1	(63.4-180.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	44	52.2	84.3	(61.2-113.2)	Female	8	14.3	56.0	(24.1-110.4)
Female	67	51.7	129.6	(100.4-164.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	11.3	106.2	(54.8-185.5)
Male	9	9.8	91.9	(41.9-174.4)	Female	10	12.3	81.3	(38.9-149.6)
Female	1	2.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	133	142.7	93.2	(78.0-110.5)
Male	5	2.8	177.7	(57.3-414.7)	<u>Stomach</u>				
Female	4	2.3	nc	(nc-nc)	Male	9	8.5	105.9	(48.3-201.0)
<u>Kidney & Renal Pelvis</u>					Female	6	5.6	106.6	(38.9-232.0)
Male	17	17.6	96.5	(56.2-154.6)	<u>Testis</u>				
Female	15	11.1	134.7	(75.3-222.1)	Male	5	4.6	108.4	(34.9-252.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	6.1	164.1	(78.6-301.8)	Male	3	5.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	23	17.8	129.6	(82.1-194.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	11.9	58.6	(23.5-120.8)	Female	31	30.6	101.3	(68.8-143.8)
Female	7	9.7	72.0	(28.8-148.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	505	495.7	101.9	(93.2-111.2)
Male	10	8.8	114.2	(54.7-210.0)	Female	499	480.0	104.0	(95.0-113.5)
Female	2	3.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	80	69.3	115.4	(91.5-143.6)					
Female	73	68.3	106.9	(83.8-134.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	6	4.6	129.9	(47.4-282.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	2.1	nc	(nc-nc)	Female	14	15.7	89.4	(48.8-150.0)
Female	1	1.7	nc	(nc-nc)	Female	11	13.2	83.5	(41.6-149.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1	2.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	14.9	73.7	(36.7-131.8)	Male	9	10.0	90.3	(41.2-171.4)
Female	5	5.5	90.7	(29.2-211.6)	Female	11	8.6	127.8	(63.7-228.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	8.5	94.5	(40.7-186.1)
Female	70	58.7	119.2	(92.9-150.6)	Female	10	7.5	133.9	(64.1-246.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.8	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	21.6	83.5	(49.5-132.0)	Female	5	6.1	82.6	(26.6-192.8)
Female	21	20.0	105.1	(65.0-160.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.6	130.6	(47.7-284.2)
Male	6	4.0	148.5	(54.2-323.2)	Female	5	4.7	105.8	(34.1-246.9)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	48	57.9	82.8	(61.1-109.8)
Male	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.2	nc	(nc-nc)
Male	10	7.5	133.1	(63.7-244.7)	<u>Testis</u>				
Female	8	4.6	172.2	(74.1-339.3)	Male	2	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.5	nc	(nc-nc)	Male	6	2.7	219.8	(80.3-478.5)
Female	1	0.7	nc	(nc-nc)	Female	8	9.0	89.2	(38.4-175.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.2	115.6	(42.2-251.5)	Female	12	13.0	92.2	(47.6-161.1)
Female	5	4.1	122.1	(39.3-284.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	183	206.4	88.7	(76.3-102.5)
Male	1	3.7	nc	(nc-nc)	Female	212	200.6	105.7	(91.9-120.9)
Female	2	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	28.1	92.4	(60.3-135.4)					
Female	25	27.2	92.0	(59.5-135.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.7	120.3	(51.8-237.0)	Male	3	4.3	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	32	24.2	132.4	(90.6-186.9)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.6	104.5	(50.0-192.1)	Female	0	2.5	nc	(nc-nc)
Female	8	7.9	100.9	(43.4-198.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.1	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	25	26.8	93.4	(60.4-137.9)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.8	nc	(nc-nc)
Male	5	3.3	150.3	(48.5-350.9)	<u>Testis</u>				
Female	2	1.9	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.2	nc	(nc-nc)	Female	5	5.5	91.0	(29.3-212.4)
Female	1	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	85	92.2	92.2	(73.7-114.1)
Male	1	1.7	nc	(nc-nc)	Female	72	81.2	88.6	(69.3-111.6)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	12.6	102.9	(54.7-176.0)					
Female	9	11.1	81.0	(37.0-153.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	3	5.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	6.4	77.8	(25.1-181.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	17	22.1	76.8	(44.7-123.0)
Male	0	0.4	nc	(nc-nc)	Female	16	19.3	83.0	(47.4-134.9)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	3.0	nc	(nc-nc)					
Female	2	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.1	99.0	(47.4-182.1)	Male	6	5.8	103.0	(37.6-224.2)
Female	5	4.2	120.4	(38.8-281.0)	Female	4	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
Female	33	35.9	91.8	(63.2-128.9)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	13.9	115.1	(65.8-187.0)	Female	2	3.9	nc	(nc-nc)
Female	17	15.5	109.5	(63.7-175.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.0	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	5	3.7	136.8	(44.1-319.2)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	48	35.2	136.2	(100.4-180.6)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<u>Testis</u>				
Female	3	3.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	4.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.2	nc	(nc-nc)	Female	8	8.0	100.5	(43.3-198.1)
Female	3	2.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	141	127.4	110.7	(93.2-130.6)
Male	1	2.2	nc	(nc-nc)	Female	118	132.1	89.3	(74.0-107.0)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	18.1	143.4	(93.6-210.1)					
Female	17	19.0	89.3	(52.0-143.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	22.4	67.0	(37.5-110.5)	Male	6	13.2	45.5	(16.6-99.1)
Female	9	9.3	96.4	(44.0-182.9)	Female	9	11.5	78.5	(35.8-149.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.8	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	8	11.4	69.9	(30.1-137.8)
Female	94	80.9	116.2	(93.9-142.2)	Female	13	11.8	109.9	(58.5-188.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.3	184.2	(67.2-400.9)	Male	12	7.8	153.1	(79.0-267.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	30.8	77.8	(49.8-115.8)	Female	7	8.7	80.1	(32.1-165.1)
Female	28	35.4	79.1	(52.6-114.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	6.6	105.7	(42.3-217.8)
Male	8	5.5	144.6	(62.3-285.0)	Female	10	8.3	120.9	(57.9-222.3)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	76.9	76.7	(58.4-98.9)
Male	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.4	nc	(nc-nc)	Male	6	5.2	115.7	(42.2-251.8)
<u>Kidney & Renal Pelvis</u>					Female	1	4.0	nc	(nc-nc)
Male	6	9.8	61.1	(22.3-132.9)	<u>Testis</u>				
Female	5	6.8	73.2	(23.6-170.9)	Male	3	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.4	148.7	(47.9-347.0)	Male	3	3.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	6	10.0	59.8	(21.8-130.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	7.2	nc	(nc-nc)	Female	14	17.7	79.1	(43.2-132.7)
Female	4	6.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	253	282.9	89.4	(78.8-101.2)
Male	5	4.8	103.3	(33.3-241.1)	Female	278	299.1	92.9	(82.3-104.5)
Female	3	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	53	40.0	132.6	(99.3-173.5)					
Female	34	42.3	80.3	(55.6-112.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	7.6	171.4	(91.2-293.2)	Male	5	5.7	88.3	(28.5-206.1)
Female	4	2.6	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.8	146.9	(58.8-302.7)
Female	36	32.5	110.7	(77.5-153.2)	Female	3	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	11.5	121.9	(66.6-204.5)	Female	1	3.2	nc	(nc-nc)
Female	11	9.4	117.6	(58.6-210.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.4	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	30.8	107.1	(73.7-150.4)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	6	4.3	140.8	(51.4-306.6)	<u>Testis</u>				
Female	3	2.4	nc	(nc-nc)	Male	6	1.5	387.4	(141.5-843.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	11	5.4	205.0	(102.2-366.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.9	nc	(nc-nc)	Female	10	7.0	143.2	(68.6-263.4)
Female	0	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	113	111.3	101.6	(83.7-122.1)
Male	2	2.1	nc	(nc-nc)	Female	113	103.8	108.8	(89.7-130.8)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	14.5	48.4	(19.4-99.7)					
Female	11	12.8	85.8	(42.8-153.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.0	116.0	(46.5-239.0)	Male	5	4.1	122.2	(39.4-285.3)
Female	1	2.0	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	25	23.2	107.8	(69.8-159.2)	Female	3	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	8.8	91.3	(39.3-179.8)	Female	3	2.3	nc	(nc-nc)
Female	7	7.3	95.9	(38.4-197.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.9	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	21	24.4	85.9	(53.2-131.4)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.8	nc	(nc-nc)
Male	1	3.1	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	3.5	171.6	(62.7-373.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.1	nc	(nc-nc)	Female	7	5.1	137.2	(55.0-282.7)
Female	2	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	80	85.1	94.0	(74.6-117.0)
Male	1	1.5	nc	(nc-nc)	Female	86	76.4	112.5	(90.0-139.0)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	11.6	138.0	(78.8-224.1)					
Female	16	10.1	157.9	(90.2-256.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.4	67.3	(21.7-157.1)	Male	2	4.1	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	14	24.1	58.2	(31.8-97.6)	Female	6	3.5	172.1	(62.8-374.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	10.0	149.3	(83.5-246.2)	Female	4	2.6	nc	(nc-nc)
Female	7	10.4	67.2	(26.9-138.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.2	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	5	2.4	204.3	(65.8-476.8)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	24.8	112.8	(74.9-163.0)
Male	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.2	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	5	2.8	175.7	(56.6-410.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.3	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	85	91.2	93.2	(74.5-115.3)
Male	1	1.5	nc	(nc-nc)	Female	83	88.5	93.8	(74.7-116.3)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	13.2	nc	(nc-nc)					
Female	14	12.7	110.1	(60.2-184.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.4	118.6	(56.8-218.1)	Male	6	5.3	112.5	(41.1-244.9)
Female	2	3.1	nc	(nc-nc)	Female	2	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.6	175.8	(75.7-346.4)
Female	26	31.6	82.2	(53.7-120.4)	Female	5	4.1	122.5	(39.5-286.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	3.3	179.9	(65.7-391.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	11.9	75.4	(34.4-143.2)	Female	5	3.3	153.3	(49.4-357.8)
Female	14	11.0	126.9	(69.3-212.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.6	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	32.8	79.3	(51.8-116.2)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	5	4.1	122.8	(39.6-286.5)	<u>Testis</u>				
Female	5	2.6	195.9	(63.1-457.2)	Male	1	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.8	nc	(nc-nc)	Female	5	7.1	70.1	(22.6-163.6)
Female	3	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	116	114.1	101.7	(84.0-122.0)
Male	1	2.0	nc	(nc-nc)	Female	112	108.7	103.0	(84.8-124.0)
Female	1	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	15.8	114.0	(67.5-180.2)					
Female	19	15.3	123.9	(74.6-193.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.0	87.4	(35.0-180.1)	Male	8	5.3	150.6	(64.9-296.9)
Female	1	2.5	nc	(nc-nc)	Female	5	4.2	119.9	(38.6-279.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	28	28.8	97.3	(64.6-140.6)	Female	6	3.5	173.4	(63.3-377.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	5	3.3	151.3	(48.8-353.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	11.5	139.2	(79.5-226.0)	Female	5	2.9	171.5	(55.3-400.3)
Female	16	9.1	176.0	(100.5-285.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.5	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	Female	5	2.2	231.2	(74.5-539.5)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	32	30.9	103.6	(70.8-146.2)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	0	4.0	nc	(nc-nc)	<u>Testis</u>				
Female	4	2.2	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.8	nc	(nc-nc)	Female	8	6.3	126.4	(54.4-249.1)
Female	3	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	104	110.1	94.5	(77.2-114.5)
Male	2	2.0	nc	(nc-nc)	Female	104	95.6	108.8	(88.9-131.8)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	15.0	46.5	(18.6-95.9)					
Female	7	12.7	55.1	(22.1-113.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.1	82.4	(26.5-192.2)	Male	2	3.9	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	0	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	27	22.6	119.7	(78.9-174.2)	Female	2	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	8.7	91.9	(39.6-181.1)	Female	1	2.3	nc	(nc-nc)
Female	12	8.0	150.1	(77.5-262.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.7	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	24.5	85.6	(53.0-130.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	3.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	2.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.5	nc	(nc-nc)	Female	5	5.1	98.4	(31.7-229.6)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	11	11.5	95.6	(47.7-171.1)	Male	63	83.7	75.3	(57.8-96.3)
Female	13	10.4	124.7	(66.3-213.3)	Female	81	76.8	105.5	(83.8-131.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	4.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	2	4.9	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	8	16.4	48.9	(21.1-96.3)
Male	0	0.3	nc	(nc-nc)	Female	9	13.3	67.5	(30.8-128.2)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	2.2	nc	(nc-nc)					
Female	1	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	12.4	137.2	(79.9-219.7)	Male	13	8.6	151.8	(80.7-259.6)
Female	9	4.9	182.1	(83.1-345.6)	Female	9	7.4	121.3	(55.3-230.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.2	138.3	(66.2-254.3)
Female	35	53.7	65.2	(45.4-90.7)	Female	5	6.7	75.1	(24.2-175.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	18.3	125.7	(79.6-188.6)	Female	5	5.5	91.2	(29.4-212.9)
Female	22	17.9	123.2	(77.2-186.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.9	nc	(nc-nc)
Male	6	3.5	169.1	(61.7-368.0)	Female	6	4.2	141.7	(51.7-308.4)
Female	3	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	56	52.2	107.4	(81.1-139.4)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.9	nc	(nc-nc)
Male	6	6.6	91.1	(33.2-198.2)	<u>Testis</u>				
Female	6	4.2	143.0	(52.2-311.2)	Male	2	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.2	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	15	7.6	198.0	(110.7-326.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.4	nc	(nc-nc)	Female	11	12.1	91.2	(45.5-163.2)
Female	3	3.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	190	178.5	106.4	(91.8-122.7)
Male	1	3.3	nc	(nc-nc)	Female	164	180.1	91.0	(77.6-106.1)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	23.8	75.5	(44.7-119.3)					
Female	16	24.5	65.3	(37.3-106.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.4	142.2	(73.4-248.5)	Male	7	6.0	117.2	(47.0-241.5)
Female	3	2.9	nc	(nc-nc)	Female	7	4.9	141.7	(56.8-292.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	5	1.4	354.0	(114.1-826.1)
Female	2	1.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	33	34.7	95.1	(65.4-133.5)	Female	4	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	6	4.0	151.8	(55.4-330.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	12.5	143.7	(85.1-227.2)	Female	3	3.5	nc	(nc-nc)
Female	12	10.5	114.2	(59.0-199.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	2.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	35	36.3	96.5	(67.2-134.2)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	4.6	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.6	nc	(nc-nc)	Male	5	1.5	327.9	(105.7-765.3)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	3.0	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	12	5.3	224.5	(115.8-392.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.3	nc	(nc-nc)	Female	10	7.8	127.8	(61.2-235.1)
Female	2	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	19	16.4	115.7	(69.7-180.8)	Male	143	123.6	115.7	(97.5-136.3)
Female	24	14.8	161.6	(103.5-240.5)	Female	136	113.3	120.0	(100.7-141.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	13	10.2	127.0	(67.6-217.3)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	4.1	147.4	(53.8-320.8)	Female	1	1.1	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.9	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	11.0	91.3	(43.7-167.9)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.0	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	44	38.6	113.9	(82.7-152.9)
Male	0	0.7	nc	(nc-nc)	Female	32	36.1	88.7	(60.7-125.3)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	5.4	186.3	(89.2-342.7)					
Female	2	5.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	26.8	93.2	(60.3-137.5)	Male	26	13.6	191.3	(124.9-280.3)
Female	13	10.2	127.8	(68.0-218.6)	Female	22	10.4	212.2	(132.9-321.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	5	3.9	129.2	(41.7-301.6)
Female	6	3.3	183.9	(67.1-400.2)	Female	2	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	12	12.0	99.7	(51.5-174.2)
Female	81	78.6	103.1	(81.8-128.1)	Female	8	12.2	65.8	(28.3-129.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	9	7.6	117.8	(53.7-223.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	35.0	74.3	(48.5-108.9)	Female	4	8.6	nc	(nc-nc)
Female	35	37.1	94.3	(65.7-131.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	7.7	156.6	(80.8-273.6)
Male	7	6.2	113.7	(45.6-234.3)	Female	15	8.9	168.9	(94.5-278.6)
Female	0	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	107	87.2	122.7	(100.6-148.3)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.0	nc	(nc-nc)	Male	5	6.0	83.1	(26.8-193.9)
<u>Kidney & Renal Pelvis</u>					Female	5	4.2	120.2	(38.7-280.6)
Male	8	10.4	77.1	(33.2-151.9)	<u>Testis</u>				
Female	7	7.1	98.7	(39.5-203.3)	Male	7	1.5	457.2	(183.2-942.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.7	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	5	7.8	63.8	(20.6-148.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	7.6	nc	(nc-nc)	Female	21	17.6	119.1	(73.7-182.1)
Female	6	6.4	93.7	(34.2-204.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	326	314.7	103.6	(92.6-115.5)
Male	5	5.0	100.5	(32.4-234.6)	Female	302	301.7	100.1	(89.1-112.0)
Female	1	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	47.4	65.4	(44.4-92.9)					
Female	45	46.9	96.0	(70.0-128.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	4.6	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	24	15.7	152.6	(97.8-227.1)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	6	5.9	100.9	(36.9-219.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.4	nc	(nc-nc)
Male	4	1.2	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	17	17.7	95.8	(55.8-153.4)
Male	3	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.6	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	57	61.3	93.0	(70.4-120.5)
Male	0	1.1	nc	(nc-nc)	Female	59	55.0	107.2	(81.6-138.3)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	8.6	81.0	(32.5-167.0)					
Female	7	7.9	88.6	(35.5-182.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	57.8	84.8	(62.7-112.1)	Male	25	36.6	68.3	(44.2-100.8)
Female	24	23.8	100.7	(64.5-149.8)	Female	29	33.1	87.7	(58.7-126.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.4	78.8	(35.9-149.6)	Male	4	9.0	nc	(nc-nc)
Female	5	10.4	48.1	(15.5-112.3)	Female	5	7.6	66.1	(21.3-154.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	25	31.4	79.5	(51.5-117.4)
Female	185	226.1	81.8	(70.5-94.5)	Female	28	31.0	90.2	(59.9-130.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	10.2	78.5	(33.8-154.6)	Male	16	21.9	73.2	(41.8-118.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	82	81.1	101.1	(80.4-125.5)	Female	25	23.9	104.7	(67.7-154.5)
Female	92	88.1	104.4	(84.2-128.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	17.4	109.4	(65.8-170.8)
Male	18	14.8	121.3	(71.9-191.8)	Female	16	20.7	77.2	(44.1-125.3)
Female	8	4.6	172.7	(74.4-340.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	173	209.2	82.7	(70.8-96.0)
Male	4	5.3	nc	(nc-nc)	<u>Stomach</u>				
Female	4	4.6	nc	(nc-nc)	Male	11	13.4	81.9	(40.8-146.5)
<u>Kidney & Renal Pelvis</u>					Female	7	9.8	71.6	(28.7-147.5)
Male	33	27.2	121.4	(83.5-170.5)	<u>Testis</u>				
Female	18	18.5	97.1	(57.5-153.5)	Male	11	9.4	117.2	(58.4-209.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	11	9.1	120.7	(60.2-215.9)	Male	8	9.6	83.7	(36.1-165.0)
Female	3	2.7	nc	(nc-nc)	Female	24	32.1	74.7	(47.9-111.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	22	19.8	111.0	(69.6-168.1)	Female	60	49.6	121.1	(92.4-155.8)
Female	21	17.3	121.2	(75.0-185.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	710	763.8	93.0	(86.2-100.1)
Male	16	13.2	120.9	(69.1-196.4)	Female	741	808.5	91.7	(85.2-98.5)
Female	5	5.2	97.0	(31.3-226.3)					
<u>Lung and Bronchus</u>									
Male	113	105.5	107.1	(88.3-128.8)					
Female	111	112.0	99.1	(81.5-119.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	2	2.4	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	4	7.8	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.1	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	2	3.9	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	12.9	85.5	(42.6-152.9)
Male	0	0.2	nc	(nc-nc)	Female	5	9.6	52.0	(16.7-121.2)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.8	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	24.2	57.8	(31.6-97.0)	Male	26	15.2	171.4	(111.9-251.1)
Female	15	9.6	157.0	(87.8-259.0)	Female	22	12.8	172.1	(107.8-260.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.5	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	5	4.0	124.1	(40.0-289.7)	Female	4	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	20	12.9	154.6	(94.4-238.7)
Female	97	95.1	102.0	(82.7-124.5)	Female	13	12.4	105.1	(55.9-179.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.9	nc	(nc-nc)	Male	6	9.8	61.1	(22.3-133.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	34.4	98.7	(68.3-137.9)	Female	3	9.9	nc	(nc-nc)
Female	35	34.8	100.7	(70.1-140.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	7.5	93.5	(37.4-192.6)
Male	8	6.6	121.6	(52.4-239.7)	Female	11	8.2	133.5	(66.5-238.8)
Female	2	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	88	96.6	91.1	(73.0-112.2)
Male	0	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.4	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	3.8	nc	(nc-nc)
Male	8	11.8	67.5	(29.1-133.0)	<u>Testis</u>				
Female	14	7.6	183.1	(100.0-307.2)	Male	7	2.7	254.8	(102.1-525.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.1	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	17	12.1	140.3	(81.7-224.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.9	101.1	(43.5-199.2)	Female	20	21.6	92.8	(56.7-143.3)
Female	4	6.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	293	329.7	88.9	(79.0-99.7)
Male	4	5.9	nc	(nc-nc)	Female	344	328.4	104.8	(94.0-116.4)
Female	2	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	45.8	58.9	(38.8-85.8)					
Female	43	46.1	93.3	(67.5-125.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.9	nc	(nc-nc)	Male	6	1.3	473.4	(172.9-1030.5)
Female	1	0.6	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	8	6.8	117.9	(50.7-232.2)	Female	3	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.8	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	6	2.2	271.4	(99.1-590.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	11	8.0	137.0	(68.3-245.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.0	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.5	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Male</u>					<u>Female</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	13.3	90.0	(46.4-157.2)	Male	6	8.0	74.6	(27.3-162.5)
Female	6	4.8	124.0	(45.3-270.0)	Female	6	6.4	94.2	(34.4-205.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.9	72.6	(23.4-169.4)
Female	45	46.2	97.5	(71.1-130.4)	Female	4	6.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	6	4.9	122.4	(44.7-266.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	18.5	65.0	(33.6-113.6)	Female	6	4.8	124.5	(45.5-271.0)
Female	13	17.0	76.7	(40.8-131.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.0	nc	(nc-nc)
Male	6	3.4	174.2	(63.6-379.2)	Female	5	4.1	121.7	(39.2-284.0)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	34	50.5	67.3	(46.6-94.0)
Male	3	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	3.0	165.4	(53.3-386.0)
<u>Kidney & Renal Pelvis</u>					Female	3	1.8	nc	(nc-nc)
Male	4	6.2	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.8	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	2.1	279.6	(102.1-608.7)	Male	5	2.0	252.1	(81.2-588.3)
Female	1	0.6	nc	(nc-nc)	Female	5	6.1	82.2	(26.5-191.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.2	nc	(nc-nc)	Female	13	10.5	123.9	(65.9-211.9)
Female	4	3.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	155	175.6	88.3	(74.9-103.3)
Male	4	3.0	nc	(nc-nc)	Female	165	162.5	101.6	(86.7-118.3)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	25.0	120.1	(81.0-171.4)					
Female	31	23.9	129.8	(88.1-184.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	19.2	88.6	(51.6-141.9)	Male	14	12.0	116.3	(63.5-195.1)
Female	5	6.9	72.9	(23.5-170.0)	Female	10	9.5	105.1	(50.3-193.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.6	138.7	(44.7-323.7)	Male	5	3.0	164.0	(52.8-382.6)
Female	4	3.0	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	9	10.3	87.4	(39.9-166.0)
Female	70	69.3	101.1	(78.8-127.7)	Female	8	9.0	88.6	(38.2-174.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	9	7.7	117.1	(53.4-222.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	27.3	69.6	(41.9-108.7)	Female	8	7.2	111.6	(48.1-220.0)
Female	22	25.2	87.3	(54.7-132.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.9	152.9	(69.8-290.2)
Male	2	5.1	nc	(nc-nc)	Female	3	6.0	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	68	73.9	92.0	(71.5-116.7)
Male	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.7	nc	(nc-nc)
Male	8	9.3	86.3	(37.2-170.1)	<u>Testis</u>				
Female	3	5.5	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.2	nc	(nc-nc)	Male	5	3.0	165.4	(53.3-385.9)
Female	0	0.8	nc	(nc-nc)	Female	10	9.2	108.5	(52.0-199.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.3	111.1	(44.5-229.0)	Female	9	15.4	58.4	(26.7-110.9)
Female	2	4.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	234	258.0	90.7	(79.4-103.1)
Male	3	4.6	nc	(nc-nc)	Female	201	238.8	84.2	(72.9-96.6)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	35.7	78.3	(52.0-113.2)					
Female	20	33.1	60.4	(36.9-93.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	4	7.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	3.3	179.7	(65.6-391.2)	Female	0	0.8	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	10	9.2	109.2	(52.3-200.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.8	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.6	nc	(nc-nc)	Male	32	32.2	99.2	(67.9-140.1)
Female	0	0.1	nc	(nc-nc)	Female	23	25.3	90.8	(57.5-136.2)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)					
Female	5	3.2	156.5	(50.4-365.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.0	91.8	(45.8-164.3)	Male	7	8.6	81.7	(32.7-168.4)
Female	7	4.2	168.0	(67.3-346.2)	Female	9	7.1	127.3	(58.1-241.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.8	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.2	83.5	(30.5-181.8)
Female	55	51.0	107.8	(81.2-140.3)	Female	6	5.8	103.5	(37.8-225.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.4	nc	(nc-nc)	Male	9	5.7	157.1	(71.7-298.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	18.0	116.9	(72.3-178.7)	Female	5	5.1	98.4	(31.7-229.7)
Female	11	14.9	73.7	(36.8-131.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.8	155.9	(56.9-339.4)
Male	5	3.5	142.2	(45.8-331.8)	Female	8	3.5	226.3	(97.4-445.9)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	67	51.7	129.6	(100.4-164.6)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.5	nc	(nc-nc)
Male	9	6.6	136.1	(62.1-258.4)	<u>Testis</u>				
Female	4	3.8	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.2	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	9	7.7	116.9	(53.4-222.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.3	nc	(nc-nc)	Female	10	11.4	87.7	(42.0-161.2)
Female	1	3.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	199	176.3	112.9	(97.7-129.7)
Male	2	3.3	nc	(nc-nc)	Female	158	163.6	96.6	(82.1-112.9)
Female	3	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	23.3	98.6	(62.5-147.9)					
Female	11	21.2	51.8	(25.8-92.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	43.7	75.6	(52.0-106.2)	Male	15	25.5	58.7	(32.8-96.9)
Female	17	17.9	95.0	(55.3-152.1)	Female	21	22.8	92.3	(57.1-141.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	7.8	nc	(nc-nc)	Male	6	6.6	90.7	(33.1-197.4)
Female	8	7.4	108.8	(46.9-214.4)	Female	6	5.6	106.3	(38.8-231.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	16	22.3	71.6	(40.9-116.3)
Female	140	156.4	89.5	(75.3-105.6)	Female	25	22.7	109.9	(71.1-162.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.6	75.4	(24.3-175.9)	Male	18	15.0	120.3	(71.3-190.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	53	59.7	88.8	(66.5-116.2)	Female	17	16.9	100.6	(58.6-161.0)
Female	68	66.8	101.7	(79.0-129.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	12.9	132.1	(76.9-211.5)
Male	16	10.7	149.0	(85.1-242.1)	Female	14	15.7	89.2	(48.8-149.8)
Female	1	3.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	138	151.3	91.2	(76.6-107.8)
Male	2	3.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.1	nc	(nc-nc)	Male	8	10.0	79.8	(34.4-157.3)
<u>Kidney & Renal Pelvis</u>					Female	6	7.5	79.6	(29.1-173.2)
Male	8	19.1	41.8	(18.0-82.4)	<u>Testis</u>				
Female	17	13.2	128.6	(74.9-205.9)	Male	4	5.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	6.6	106.8	(42.8-220.2)	Male	4	6.1	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	13	20.7	62.8	(33.4-107.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	14.5	83.0	(42.8-145.0)	Female	50	34.4	145.3	(107.9-191.6)
Female	13	12.9	101.2	(53.8-173.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	478	553.5	86.4	(78.8-94.5)
Male	8	9.3	86.3	(37.2-170.1)	Female	564	579.3	97.4	(89.5-105.7)
Female	1	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	73	78.5	93.0	(72.9-116.9)					
Female	89	81.8	108.7	(87.3-133.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.1	126.2	(57.6-239.6)	Male	5	4.3	115.8	(37.3-270.2)
Female	0	2.7	nc	(nc-nc)	Female	0	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	23	25.9	89.0	(56.4-133.5)	Female	3	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	9.9	60.7	(22.2-132.1)	Female	2	2.7	nc	(nc-nc)
Female	8	10.2	78.6	(33.9-155.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.1	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	24.6	105.5	(68.9-154.6)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.1	nc	(nc-nc)
Male	5	3.2	155.3	(50.0-362.4)	<u>Testis</u>				
Female	2	2.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.3	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	84	91.2	92.2	(73.5-114.1)
Male	1	1.6	nc	(nc-nc)	Female	74	92.0	80.5	(63.2-101.0)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	12.9	101.1	(53.8-172.9)					
Female	7	12.8	54.6	(21.9-112.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.4	106.2	(50.9-195.4)	Male	4	7.3	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	Female	6	6.4	93.5	(34.1-203.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	6.1	114.0	(45.7-235.0)
Female	47	43.4	108.4	(79.6-144.1)	Female	4	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	14.6	75.6	(37.7-135.2)	Female	7	4.3	162.6	(65.1-335.1)
Female	8	12.9	61.9	(26.6-121.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	3.0	263.8	(113.6-519.9)
Male	2	2.8	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	38.7	111.2	(80.5-149.8)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.4	nc	(nc-nc)
Male	2	5.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	3.2	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	1.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	10	7.3	136.9	(65.5-251.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.7	nc	(nc-nc)	Female	9	9.1	99.2	(45.2-188.2)
Female	2	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	125	141.1	88.6	(73.7-105.5)
Male	5	2.8	181.4	(58.5-423.4)	Female	126	139.8	90.1	(75.1-107.3)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	18.0	55.5	(26.5-102.0)					
Female	11	17.0	64.5	(32.2-115.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	2.9	273.9	(117.9-539.7)	Male	1	2.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	20	12.6	159.0	(97.1-245.6)	Female	2	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	4.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.9	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	12.7	142.3	(84.3-224.9)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.4	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.1	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	51	44.8	113.9	(84.8-149.8)
Male	0	0.9	nc	(nc-nc)	Female	49	40.0	122.5	(90.6-162.0)
Female	0	0.2	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	5	5.7	87.2	(28.1-203.5)	<u>Bladder, Urinary</u>				
Female	5	4.8	103.9	(33.5-242.5)	Male	8	2.9	273.9	(117.9-539.7)
<u>Lung and Bronchus</u>					Female	1	1.0	nc	(nc-nc)
Male	5	5.7	87.2	(28.1-203.5)	<u>Brain and Other Nervous System</u>				
Female	5	4.8	103.9	(33.5-242.5)	Male	0	0.8	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	18.8	96.0	(56.9-151.7)	Male	9	12.4	72.5	(33.1-137.6)
Female	12	7.1	169.9	(87.7-296.8)	Female	9	10.2	88.1	(40.2-167.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.8	130.6	(42.1-304.7)	Male	2	3.0	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	10.5	66.6	(26.7-137.2)
Female	72	72.5	99.4	(77.7-125.1)	Female	13	9.3	139.8	(74.3-239.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.2	185.3	(67.7-403.3)	Male	5	7.9	63.7	(20.5-148.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	27.0	96.3	(62.9-141.1)	Female	10	7.5	133.9	(64.1-246.3)
Female	30	25.1	119.6	(80.7-170.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	5.1	nc	(nc-nc)	Male	63	75.2	83.8	(64.4-107.2)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.7	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	9.5	94.8	(43.3-180.0)	Female	10	16.3	61.3	(29.3-112.7)
Female	5	5.8	85.7	(27.6-200.1)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	3.2	nc	(nc-nc)	Male	8	6.4	125.6	(54.1-247.4)
Female	1	0.9	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	4	4.7	nc	(nc-nc)	Male	51	35.7	143.0	(106.4-188.0)
Female	1	1.5	nc	(nc-nc)	Female	29	35.0	82.8	(55.4-118.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	12.4	177.7	(111.3-269.0)	Male	11	8.1	135.4	(67.5-242.2)
Female	7	4.3	162.7	(65.2-335.3)	Female	10	6.6	150.7	(72.1-277.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	6	6.8	87.6	(32.0-190.8)
Female	50	48.2	103.6	(76.9-136.6)	Female	6	5.8	103.2	(37.7-224.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	8	5.2	152.5	(65.7-300.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	17.9	122.8	(76.9-185.9)	Female	11	4.9	225.6	(112.5-403.7)
Female	18	15.2	118.3	(70.1-187.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.9	nc	(nc-nc)
Male	7	3.4	204.6	(82.0-421.6)	Female	3	3.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	50.6	106.8	(80.2-139.3)
Male	3	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	1.6	nc	(nc-nc)
Male	8	6.3	127.3	(54.8-250.8)	<u>Testis</u>				
Female	6	3.7	161.2	(58.9-350.8)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	2.2	278.4	(101.7-606.1)	Male	3	2.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	10	6.9	145.6	(69.7-267.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	4.1	171.6	(68.7-353.5)	Female	13	11.0	117.8	(62.7-201.5)
Female	7	3.0	233.3	(93.5-480.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	218	172.6	126.3	(110.1-144.2)
Male	3	3.1	nc	(nc-nc)	Female	205	159.3	128.7	(111.7-147.5)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	23.7	109.9	(71.7-161.0)					
Female	32	21.9	146.4	(100.1-206.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	2.1	238.6	(76.9-556.8)	Male	3	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	9	7.8	115.0	(52.5-218.2)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	8.8	91.2	(39.3-179.7)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	36	30.1	119.5	(83.7-165.4)
Male	0	0.6	nc	(nc-nc)	Female	26	26.2	99.1	(64.7-145.2)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	4.0	151.3	(55.2-329.3)					
Female	2	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	15.9	113.2	(67.0-178.8)	Male	10	10.0	100.3	(48.0-184.5)
Female	6	6.5	92.3	(33.7-200.8)	Female	13	8.5	153.0	(81.4-261.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.9	169.7	(54.7-396.0)	Male	1	2.5	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.5	117.7	(56.3-216.4)
Female	64	62.6	102.2	(78.7-130.5)	Female	11	8.4	131.4	(65.5-235.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	7	6.4	109.7	(44.0-226.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	22.7	61.8	(33.8-103.7)	Female	9	6.5	137.6	(62.8-261.3)
Female	38	23.9	158.9	(112.4-218.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	4.3	nc	(nc-nc)	Male	80	61.8	129.4	(102.6-161.1)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.2	nc	(nc-nc)	Male	6	1.9	318.4	(116.3-693.0)
Female	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	7.7	155.0	(80.0-270.8)	Female	15	14.0	107.2	(59.9-176.8)
Female	2	5.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.6	nc	(nc-nc)	Male	228	214.6	106.3	(92.9-121.0)
Female	2	0.8	nc	(nc-nc)	Female	244	219.4	111.2	(97.7-126.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.1	136.2	(54.6-280.7)	<u>All Sites / Types</u>				
Female	3	4.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	26	29.9	86.9	(56.7-127.3)	<u>All Sites / Types</u>				
Female	33	30.9	106.6	(73.4-149.8)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	13.6	73.3	(35.1-134.7)	Male	13	8.4	154.9	(82.4-265.0)
Female	13	5.1	253.6	(134.9-433.6)	Female	7	7.0	100.0	(40.0-205.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.6	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.2	138.4	(66.2-254.5)
Female	49	49.1	99.7	(73.7-131.8)	Female	6	6.6	90.3	(33.0-196.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	5	5.1	98.5	(31.7-229.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	19.1	83.9	(47.9-136.2)	Female	6	5.2	116.4	(42.5-253.4)
Female	18	19.0	94.9	(56.2-149.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	3.5	nc	(nc-nc)	Male	55	49.3	111.6	(84.0-145.2)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.3	126.2	(54.4-248.8)	Female	12	10.7	111.7	(57.7-195.2)
Female	7	4.0	175.0	(70.1-360.5)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	2.1	nc	(nc-nc)	Male	5	4.5	110.8	(35.7-258.5)
Female	1	0.6	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	3.1	nc	(nc-nc)	Male	32	25.0	128.1	(87.6-180.8)
Female	0	1.1	nc	(nc-nc)	Female	23	24.1	95.5	(60.5-143.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.3	97.4	(46.6-179.1)	Male	7	6.8	102.2	(41.0-210.6)
Female	6	3.9	153.1	(55.9-333.3)	Female	3	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	33	40.3	81.8	(56.3-114.9)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	4.4	137.9	(50.3-300.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	14.8	154.9	(98.2-232.5)	Female	1	4.2	nc	(nc-nc)
Female	16	14.5	110.4	(63.1-179.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	2.8	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	46	40.7	113.1	(82.8-150.9)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	8	5.2	153.3	(66.0-302.0)	Male	2	2.4	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	1.8	nc	(nc-nc)	Male	5	1.6	315.6	(101.7-736.4)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	3.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	5	5.8	86.7	(27.9-202.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.6	nc	(nc-nc)	Female	7	8.8	79.4	(31.8-163.6)
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	18	19.3	93.1	(55.2-147.2)	Male	152	142.5	106.7	(90.4-125.0)
Female	21	18.6	112.8	(69.8-172.4)	Female	118	138.7	85.1	(70.4-101.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.7	106.1	(38.7-231.0)	Male	4	4.3	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	25	20.7	120.7	(78.1-178.2)	Female	0	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	8.5	94.3	(40.6-185.7)	Female	2	2.2	nc	(nc-nc)
Female	9	7.5	119.5	(54.5-226.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	29	22.8	127.1	(85.1-182.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	3.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	2.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.5	nc	(nc-nc)	Female	10	4.6	219.7	(105.2-404.0)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	16	10.7	149.9	(85.6-243.4)	Male	90	83.0	108.5	(87.2-133.4)
Female	10	9.6	104.0	(49.8-191.4)	Female	83	72.0	115.3	(91.9-143.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.6	167.9	(61.3-365.4)	Male	6	2.3	263.6	(96.2-573.7)
Female	1	1.1	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	26	11.9	219.4	(143.3-321.5)	Female	4	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	5.1	98.1	(31.6-228.8)	Female	2	1.2	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	14.2	98.8	(54.0-165.9)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.8	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	7	6.8	103.5	(41.5-213.3)	Male	58	48.8	118.9	(90.3-153.7)
Female	6	5.5	109.2	(39.9-237.6)	Female	60	40.0	150.2	(114.6-193.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	55	54.2	101.5	(76.4-132.1)	Male	16	36.8	43.4	(24.8-70.5)
Female	22	22.2	99.0	(62.0-149.8)	Female	12	35.1	34.1	(17.6-59.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	12.9	116.4	(65.1-192.0)	Male	8	8.6	92.7	(39.9-182.7)
Female	11	11.7	93.9	(46.8-168.0)	Female	5	7.0	71.0	(22.9-165.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.7	nc	(nc-nc)	Male	20	31.7	63.1	(38.5-97.5)
Female	159	225.0	70.7	(60.1-82.5)	Female	29	30.1	96.4	(64.5-138.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	23	11.3	203.6	(129.0-305.5)	Male	28	21.8	128.6	(85.4-185.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	65	77.4	83.9	(64.8-107.0)	Female	14	23.8	58.9	(32.2-98.8)
Female	81	82.1	98.7	(78.4-122.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	16.4	115.6	(69.6-180.6)
Male	10	14.2	70.4	(33.7-129.5)	Female	25	19.2	130.0	(84.1-191.9)
Female	4	4.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	214	199.9	107.1	(93.2-122.4)
Male	5	6.9	72.7	(23.4-169.7)	<u>Stomach</u>				
Female	6	5.9	102.4	(37.4-222.8)	Male	15	12.7	117.7	(65.8-194.1)
<u>Kidney & Renal Pelvis</u>					Female	6	9.1	66.0	(24.1-143.6)
Male	16	26.8	59.6	(34.0-96.8)	<u>Testis</u>				
Female	13	18.1	71.7	(38.1-122.6)	Male	4	12.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	8.8	91.4	(39.3-180.0)	Male	7	10.5	66.7	(26.7-137.5)
Female	5	2.6	192.1	(61.9-448.2)	Female	28	36.7	76.2	(50.6-110.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	21.1	80.6	(46.9-129.1)	Female	52	49.0	106.2	(79.3-139.3)
Female	21	18.1	115.7	(71.6-176.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	687	745.8	92.1	(85.4-99.3)
Male	11	13.0	84.3	(42.0-150.9)	Female	676	797.0	84.8	(78.5-91.5)
Female	7	5.0	140.9	(56.5-290.3)					
<u>Lung and Bronchus</u>									
Male	106	99.6	106.4	(87.1-128.7)					
Female	85	105.5	80.6	(64.4-99.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.8	64.4	(20.8-150.4)	Male	8	4.6	172.5	(74.3-340.0)
Female	3	2.8	nc	(nc-nc)	Female	6	3.6	165.8	(60.5-360.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	25	26.3	95.0	(61.4-140.2)	Female	5	3.6	139.9	(45.1-326.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	10.8	130.1	(71.1-218.4)	Female	1	2.8	nc	(nc-nc)
Female	15	10.1	149.1	(83.4-245.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.3	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	29.2	95.9	(63.7-138.5)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	2.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	3.4	148.6	(47.9-346.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.4	nc	(nc-nc)	Female	7	5.9	117.8	(47.2-242.8)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	96	101.7	94.4	(76.5-115.3)
Male	1	1.7	nc	(nc-nc)	Female	103	93.3	110.4	(90.1-133.9)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	14.5	103.6	(58.0-170.9)					
Female	18	13.6	132.8	(78.7-209.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.6	94.0	(45.0-173.0)	Male	3	6.9	nc	(nc-nc)
Female	2	4.0	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.2	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
Female	45	39.9	112.7	(82.2-150.9)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.8	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	15.2	72.5	(36.2-129.8)	Female	1	4.2	nc	(nc-nc)
Female	14	14.5	96.5	(52.7-161.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.2	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	40.2	82.0	(56.4-115.1)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.6	nc	(nc-nc)
Male	7	5.2	135.1	(54.1-278.3)	<u>Testis</u>				
Female	1	3.2	nc	(nc-nc)	Male	5	1.7	299.9	(96.6-699.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.7	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	5.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.6	164.6	(60.1-358.2)	Female	9	8.8	102.0	(46.6-193.7)
Female	1	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	122	144.1	84.7	(70.3-101.1)
Male	4	2.6	nc	(nc-nc)	Female	128	139.1	92.0	(76.8-109.4)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	19.7	101.6	(62.0-156.9)					
Female	28	19.1	146.4	(97.3-211.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.8	125.1	(62.3-223.8)	Male	9	4.8	189.0	(86.2-358.8)
Female	1	3.6	nc	(nc-nc)	Female	8	3.9	202.6	(87.3-399.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.2	119.8	(38.6-279.6)
Female	31	29.5	105.2	(71.4-149.3)	Female	5	4.5	111.5	(35.9-260.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.8	101.5	(52.4-177.3)	Female	4	3.2	nc	(nc-nc)
Female	14	13.8	101.2	(55.3-169.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.6	194.9	(62.8-454.9)
Male	1	2.1	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	29.7	80.7	(51.7-120.1)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.6	nc	(nc-nc)
Male	5	3.6	139.4	(44.9-325.4)	<u>Testis</u>				
Female	0	2.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.6	nc	(nc-nc)	Female	6	6.5	91.8	(33.5-199.9)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	106	106.8	99.2	(81.3-120.0)
Male	1	1.8	nc	(nc-nc)	Female	95	111.4	85.3	(69.0-104.3)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	15.4	84.2	(44.8-143.9)					
Female	11	16.3	67.5	(33.7-120.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	41.8	79.0	(54.4-111.0)	Male	18	26.6	67.6	(40.1-106.9)
Female	15	16.6	90.5	(50.6-149.3)	Female	7	23.3	30.0	(12.0-61.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	8.3	108.9	(49.7-206.8)	Male	5	6.6	76.0	(24.5-177.3)
Female	5	7.3	68.8	(22.2-160.6)	Female	3	5.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.3	nc	(nc-nc)	Male	22	22.8	96.7	(60.6-146.4)
Female	163	160.6	101.5	(86.5-118.4)	Female	20	21.6	92.4	(56.4-142.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	7.2	nc	(nc-nc)	Male	7	16.2	43.1	(17.3-88.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	68	58.9	115.4	(89.6-146.2)	Female	19	16.8	112.9	(67.9-176.3)
Female	63	60.6	104.0	(79.9-133.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	12.7	110.5	(60.3-185.4)
Male	15	11.0	136.8	(76.5-225.6)	Female	16	14.3	111.6	(63.8-181.3)
Female	3	3.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	134	157.5	85.1	(71.3-100.8)
Male	5	3.8	132.6	(42.7-309.5)	<u>Stomach</u>				
Female	4	3.2	nc	(nc-nc)	Male	12	9.6	124.5	(64.3-217.5)
<u>Kidney & Renal Pelvis</u>					Female	10	6.7	150.2	(71.9-276.3)
Male	20	20.1	99.5	(60.8-153.8)	<u>Testis</u>				
Female	12	13.1	91.6	(47.3-160.1)	Male	10	6.6	151.2	(72.4-278.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	6.8	117.8	(50.7-232.1)	Male	5	7.0	71.5	(23.0-166.9)
Female	4	1.9	nc	(nc-nc)	Female	16	22.9	69.8	(39.9-113.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	14.1	99.0	(54.1-166.1)	Female	28	35.4	79.1	(52.5-114.3)
Female	12	11.9	100.7	(52.0-175.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	546	561.3	97.3	(89.3-105.8)
Male	11	9.8	112.3	(56.0-201.0)	Female	524	568.0	92.2	(84.5-100.5)
Female	3	3.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	85	77.8	109.2	(87.3-135.1)					
Female	69	79.1	87.2	(67.8-110.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;